New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer

Core Insights - Gilead Sciences, Inc. announced the publication of positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study in The New England Journal of Medicine, evaluating the combination of Trodelvy® and Keytruda® for treating first-line PD-L1+ metastatic triple-negative breast cancer [1] Group 1 - The ASCENT-04 study successfully met its primary endpoint of progression-free survival (PFS) with a 35% improvement, indicated by a hazard ratio (HR) of 0.65 [1]